AAAAAA

   
Results: 1-9 |
Results: 9
Effect of tropisetron on circulating catecholamines and other putative biochemical markers in serum of patients with fibromyalgia
Authors: Hocherl, K Farber, L Ladenburger, S Vosshage, D Stratz, T Muller, W Grobecker, H
Citation: K. Hocherl et al., Effect of tropisetron on circulating catecholamines and other putative biochemical markers in serum of patients with fibromyalgia, SC J RHEUM, 29, 2000, pp. 46-48
Efficacy and tolerability of tropisetron in primary fibromyalgia - a highly selective and competitive 5-HT3 receptor antagonist
Authors: Farber, L Stratz, T Bruckle, W Spath, M Pongratz, D Lautenschlager, J Kotter, I Zoller, B Peter, HH Neeck, G Alten, R Muller, W
Citation: L. Farber et al., Efficacy and tolerability of tropisetron in primary fibromyalgia - a highly selective and competitive 5-HT3 receptor antagonist, SC J RHEUM, 29, 2000, pp. 49-54
Oral treatment of fibromyalgia with tropisetron given over 28 days: influence on functional and vegetative symptoms, psychometric parameters and pain
Authors: Haus, U Varga, B Stratz, T Spath, M Muller, WG
Citation: U. Haus et al., Oral treatment of fibromyalgia with tropisetron given over 28 days: influence on functional and vegetative symptoms, psychometric parameters and pain, SC J RHEUM, 29, 2000, pp. 55-58
Results of the intravenous administration of tropisetron in fibromyalgia patients
Authors: Muller, W Stratz, T
Citation: W. Muller et T. Stratz, Results of the intravenous administration of tropisetron in fibromyalgia patients, SC J RHEUM, 29, 2000, pp. 59-62
Do predictors exist for the therapeutic effect of 5-HT3 receptor antagonists in fibromyalgia?
Authors: Stratz, T Muller, W
Citation: T. Stratz et W. Muller, Do predictors exist for the therapeutic effect of 5-HT3 receptor antagonists in fibromyalgia?, SC J RHEUM, 29, 2000, pp. 63-65
The use of 5-HT3 receptor antagonists in various rheumatic diseases - a clue to the mechanism of action of these agents in fibromyalgia?
Authors: Stratz, T Muller, W
Citation: T. Stratz et W. Muller, The use of 5-HT3 receptor antagonists in various rheumatic diseases - a clue to the mechanism of action of these agents in fibromyalgia?, SC J RHEUM, 29, 2000, pp. 66-71
The challenge of fibromyalgia: new approaches
Authors: Muller, W Pongratz, D Barlin, E Eich, W Farber, L Haus, U Lautenschlager, J Mense, S Neeck, G Offenbacher, M Spath, M Stratz, T Tolk, J Welzel, D Wiech, K Wohlgemuth, M
Citation: W. Muller et al., The challenge of fibromyalgia: new approaches, SC J RHEUM, 29, 2000, pp. 86-86
The T102C polymorphism of the 5-HT2A-receptor gene in fibromyalgia
Authors: Bondy, B Spaeth, M Offenbaecher, M Glatzeder, K Stratz, T Schwarz, M de Jonge, S Kruger, M Engel, RR Farber, L Pongratz, DE Ackenheil, M
Citation: B. Bondy et al., The T102C polymorphism of the 5-HT2A-receptor gene in fibromyalgia, NEUROBIOL D, 6(5), 1999, pp. 433-439
Spinal factors in the generation of fibromyalgia syndrome
Authors: Muller, W Kelemen, J Stratz, T
Citation: W. Muller et al., Spinal factors in the generation of fibromyalgia syndrome, Z RHEUMATOL, 57, 1998, pp. 36-42
Risultati: 1-9 |